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ess: drmehmetgencer@Summary Diffuse systemic-pulmonary anastomoses and chronic hypoxemia may
result in increase in ventricular work in bronchiectasis. We aimed to assess right
ventricular (RV) and left ventricular (LV) functions in patients with bronchiectasis by
using tissue Doppler-derived myocardial performance index (MPI), which is a novel
and more sensitive parameter than conventional ventricular function parameters.
To assess the possibility of RV and LV dysfunctions occurring in bronchiectasis, we
studied 25 patients with bronchiectasis, and compared them with 22 age- and
gender-matched control subjects. MPI, which is a combined index of both systolic
and diastolic ventricular function, was calculated for both ventricles.
RV and LV MPIs were also significantly different in patients and the controls. RV
MPI was associated with the number of involved lobe, arterial blood oxygen pressure,
and acceleration time/ejection time of pulmonary flow. LV MPI was not related to
any clinical parameter, but it was correlated only with RV MPI.
Ventricular functions are impaired in bronchiectasis. The impairment of RV
function is related to involved lung lobe number, arterial oxygen pressure, and
acceleration time/ejection time of pulmonary flow. LV dysfunction was correlated
only with RV function.
& 2006 Elsevier Ltd. All rights reserved.Introductions
Right ventricular (RV) and left ventricular (LV)
dysfunctions in patients with cystic fibrosis (CF)1,2
and those with chronic obstructive pulmonaryElsevier Ltd. All rights reserv
255 68 91;
yahoo.com (M. Gencer).disease (COPD) have been described by previous
investigators.3–6 Hypoxemia is an important factor
that is known to affect RV function in these
diseases.7,8 Pulmonary hypertension also has a
major effect on RV function and has been shown
to be associated with increased mortality in
patients with CF8 and COPD.3–5 These previous
studies suggest that alterations in RV function are a
consequence of the combination of long-standinged.
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M. Gencer et al.1934hypoxia and increased pulmonary vascular resis-
tance. Also, bronchiectasis can have important
hemodynamic consequences because of prolifera-
tion of the bronchial circulation in its vicinity.
Moreover, pulmonary dysfunction may develop in
the patients. However, there is not always a direct
correlation between the type of anatomic shunt
(cylindric, etc.) and pulmonary dysfunction mea-
sured. Reduced regional ventilation, a lesser
degree of reduction in perfusion, and decreased
ventilation–perfusion ratios are observed in areas
of bronchiectatic involvement.9,10 Although both
decreased oxygen saturation11,12 and increased
pulmonary vascular resistance have been shown in
bronchiectasis,11 there is not a study that assessed
ventricular functions in detail.
There are several methods used in assessing
ventricular function. Echocardiographic methods
are commonly used, easy to application, noninva-
sive and inexpensive. Doppler-derived myocardial
performance index (MPI) is a novel echocardio-
graphic parameter, which has combined both
systolic and diastolic functions, in assessing ven-
tricular function.13,14 Furthermore, it is shown to
be more sensitive than conventional echocardio-
graphic parameters.15–17 Also, determination of MPI
derived by Doppler requires measurement of only
two simple intervals on cardiac cycle.
In this study, we aimed to assess RV and LV
functions in patients with bronchiectasis by con-
ventional methods and tissue Doppler-derived MPI.Methods
Patient population
The target population for this study comprised
consecutive 25 patients with bronchiectasis. The
age range for the patients was between 15 and 62
years. Of the 25 patients recruited into this study,
none of them had clinical evidence of overt right-
sided heart failure. In addition, 22 healthy control
subjects were recruited. None of the control
subjects had any clinical evidence of cardiac,
pulmonary or the other system’s disease. All
individuals gave written and informed consent.
The study protocol was approved by the local Ethic
Committee.
Patients were characterized as having bronch-
iectasis, based on a history and physical examina-
tion findings consistent with the disease and a high-
resolution computed tomographic scan of the
chest.18 The patients were in steady state (defined
by no significant changes in respiratory symptomsor signs for at least 3 weeks). None of the patients
underwent surgery concerning bronchiectasis or
other thoracic disease. Patients with a history or
findings according to spirometry data and physical
examination of COPD, asthma, sleep apneas, other
concomitant lung disease, cardiovascular disorders,
obesity, and other serious acute or chronic disease
were excluded. CF was excluded on the basis of a
sweat test. Pulmonary function tests were mea-
sured between 10 and 11 am using standard
protocols as recommended by the American Thor-
acic Society, with a pulmonary function analyzer
(ZAN 530 Body pletismography, Germany).19 Forced
expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) (in percent predicted) were ob-
tained. Arterial blood gas assessment was done to
measure partial pressure of arterial oxygen blood
and partial pressure of carbon dioxide blood by
means of radial artery puncture breathing room air.Echocardiograms
In all individuals, echocardiographic examinations
were performed using a machine (Aloka Prosound
SSD 5000, Tokyo, Japan) with a 3-MHz transducer.
All the echocardiographic measurements were
performed by two experienced cardiologists, una-
ware of the patients’ clinical characteristics. All
measurements were calculated from an average of
three consecutive cardiac cycles. Correction of the
pulsed wave Doppler tissue-derived time intervals
for different heart rates was performed by dividing
the values by the square root of the cardiac cycle
length (i.e., R–R interval).20a-RV functions
RV end-systolic and end-diastolic diameters and
areas, RV fractional shortening, RV area change,
and tricuspid annular plane systolic excursion
(TAPSE)21 were obtained.
From Doppler recordings of trans-tricuspid flow,
the following variables were measured: Et, At, Et/
At ratio, and deceleration time of Et.22 The RV
systolic pressure or pulmonary artery systolic
pressure (PASP) was measured by adding the
assumed right atrial pressure of 10mmHg to this
gradient (fixed value method).23 In addition,
pulmonary artery flow acceleration time divided
by ejection time of pulmonary artery blood flow
(AT/ET) was obtained.24
Pulsed wave Doppler tissue echocardiographic
recordings were obtained from the lateral corner of
the tricuspid annulus. Then, the RV MPI (RVMPI) was
calculated as ða bÞ=b. ‘‘a’’ was equal to the sum
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Figure 1 Tissue Doppler-derived myocardial perfor-
mance index (MPI) is calculated by measuring two
intervals in same cardiac cycle from Doppler recordings:
(1) a is interval between cessation of late diastolic
annular velocity (Aa) and onset of early diastolic annular
velocity (Ea); and (2) b is equal to the ejection time (ET)
and duration of systolic annular velocity (Sa)
(MPI ¼ (ab)/b ¼ (IRT+ICT)/ET). Isovolumic relaxation
time (IRT) is measured as time interval between end of
Sa and onset of Ea. Isovolumic contraction time (ICT) is
obtained by subtracting IRT from (ab) (ICT ¼
(ab)IRT).
Bronchiectasis, ventricular function 1935of isovolumic contraction time (ICTr) and ejection
time (ETr) and isovolumic relaxation time (IRTr),
and ‘‘b’’ was measured as the duration of the
systolic annular velocity (ETr)] (Fig. 1).14b-LV functions
M-mode echocardiographic measurements were
obtained on the basis of the standards of the
American Society of Echocardiography.25 LV systolic
and diastolic dimensions, septal thickness, poster-
ior wall thickness, and left atrial diameter were
measured from the M-mode recordings at end-
diastole. LV fractional shortening was calculated.
LV ejection fraction was determined using the
formula of Teichholz et al.26
From pulsed Doppler ultrasound scanning record-
ings of the mitral inflow velocities, the following
Doppler parameters were analyzed: peak early
(Em) and late (Am) transmitral filling velocities,
the ratio of early to late peak velocities (Em/Am),
and deceleration time of Em.27Pulsed wave Doppler tissue recordings were
obtained from the lateral, septal, anterior, and
inferior side of the mitral annulus. The means of
the measurements of these sites were calculated.
As was performed for RV, the LV MPI (LVMPI) was
calculated as ða bÞ=b.14 ‘‘a’’ was equal to the sum
of isovolumic contraction time (ICT) and ejection
time (ET) and isovolumic relaxation time (IRT). ‘‘b’’
was measured as the duration of the systolic
annular velocity (ET).
The absolute difference for the same observer
was 0.0170.03, and the absolute difference
between observers was 0.0270.05 for MPI. In-
traobserver and interobserver variabilities (ex-
pressed as the absolute difference divided by the
mean of measurements) were 1%74% and 1%75%
for MPI, respectively.Statistical analysis
Results are expressed as mean71 SD or frequency
expressed as a percent. Comparisons of the results
were made with the w2-test and the Fisher’s exact
test when appropriate for categorical variables and
the unpaired-t test, and Mann–Whitney U-test
when appropriate for continuous variables. Pearson
correlation coefficient and Spearman correlation
coefficient when appropriate were used to corre-
late the MPI with the echocardiographic and
clinical indexes. Receiver-operating characteristic
(ROC) curves were constructed for RVMPI and LVMPI
for the differentiation of the patients with bronch-
iectasis from controls. A P value o0.05 was
considered to be statistically significant.Results
Study population
The clinical characteristics of the study populations
are shown in Table 1. The mean age of patients with
bronchiectasis was similar to that of the control
subjects. Also, no difference was noted in sex, body
mass index, smoking status, and diastolic blood
pressure in the patients compared with controls.
Patients with bronchiectasis had a higher systolic
blood pressure and heart rate than the control
populations. Partial pressure of arterial oxygen,
FEV1, and FVC of the patients was lower than
normal reference values. The control group con-
sisting of 22 healthy subjects was shown to have
normal pulmonary function (FEV1480%, FVC480%,
FEV1/FVC470%). None of the study population was
ARTICLE IN PRESS
Table 1 Baseline characteristics of the patients with bronchiectasis and controls.
Patients with bronchiectasis
(n ¼ 25)
Controls (n ¼ 22) P-value
Age 39713 38710 0.707
Male gender 16 (64) 13 (59) 0.684
Smoker 4 (16) 3 (14) 0.812
Body mass index (kg/m2) 25.574.9 25.072.7 0.688
Systolic blood pressure (mmHg) 120711 109716 0.024
Diastolic blood pressure (mmHg) 75710 73712 0.646
Heart rate (beats/min) 83712 6877 o0.001
% predicted FEV1 (%) 7676 —
% predicted FVC (%) 7279 —
FEV1/FVC 82714 —
PaCO2 (mmHg) 39.173.2 —
PaO2 (mmHg) 79.0716.0 —
Patients with bilateral bronchiectasis
(%)
10 (40) —
Lung lobes with bronchiectasis —
One lobe 7 (28) —
Two lobes 9 (36) —
Three lobes 4 (16) —
Four lobes 5 (20) —
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity. PaCO2, partial pressure of carbon dioxide in arterial blood;
PaO2, partial pressure of oxygen in arterial blood.
Table 2 Right heart echocardiographic findings.
Patients with bronchiectasis
(n ¼ 25)
Controls (n ¼ 22) P-value
Right atrium (mm) 3575 3475 0.663
RVEDD (mm) 3375 3272 0.603
RVESD (mm) 2375 2372 0.606
RVFS (%) 2877 2875 0.868
RV diastolic area (mm2) 17.175.3 18.973.9 0.314
RV systolic area (mm2) 8.673.0 10.172.6 0.187
RV area change (%) 5078 4678 0.323
TAPSE (mm) 21.673.5 22.973.4 0.239
PASP (mmHg) 22.576.2 19.373.7 0.128
Pulmonary AT/ET 0.3770.11 0.4970.06 0.012
Et (cm/s) 46710 49712 0.349
At (cm/s) 40714 3377 0.069
Et/At 1.270.4 1.570.4 0.026
Deceleration time of Et (ms) 264772 235749 0.156
IRTr (ms) 105734 74716 0.001
ICTr (ms) 76728 60719 0.043
ETr (ms) 281736 306723 0.012
RVMPI 0.6670.19 0.4470.06 o0.001
At, late diastolic tricuspid in-flow velocity; Et, early diastolic tricuspid in-flow velocity; ETr, tissue Doppler-derived heart-rate-
corrected right ventricular ejection time; ICTr, tissue Doppler-derived heart-rate-corrected right ventricular isovolumic
contraction time; IRTr, tissue Doppler-derived heart-rate-corrected right ventricular isovolumic relaxation time; PASP,
pulmonary arterial systolic pressure; pulmonary AT/ET, ratio of pulmonary acceleration time to pulmonary ejection time; RV,
right ventricle; RVEDD, right ventricular end-diastolic diameter; RVESD, right ventricular end-systolic diameter; RVFS, right
ventricular fractional shortening; RVMPI, tissue Doppler-derived right ventricular myocardial performance index; TAPSE,
tricuspid annular plane systolic excursion.
M. Gencer et al.1936
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Figure 2 Comparison of the tissue Doppler-derived RVMPI, IRTr, ICTr, and ETr between the patients with bronchiectasis
and controls. [IRTr, tissue Doppler-derived heart-rate-corrected right ventricular isovolumic relaxation time; ICTr, tissue
Doppler-derived heart-rate-corrected right ventricular isovolumic contraction time; ETr, tissue Doppler-derived heart-
rate-corrected right ventricular ejection time; RVMPI, tissue Doppler-derived right ventricular myocardial performance
index.]
Bronchiectasis, ventricular function 1937known to have prior cardiac disease, nor were they
receiving any cardiac medications.RV function
None of the patients had RV myocardial hypokin-
esis, or flattening or compression of the interven-
tricular septum. RV structural and functional
echocardiographic parameters are shown in Table
2. Right atrial dimension, RV dimensions, and RV
systolic and diastolic areas were not different
between the groups (P40.05 for all). RV systolic
function (assessed by RV fractional shortening, RV
area change, and TAPSE) was also not different
(P40.05 for all). Although PASP was found to tend
to be higher in the patients than in the controls,
the difference was not significant (P40.05),
whereas ET/AT ratio of pulmonary flow was
significantly different (P ¼ 0.012). There were
insignificant differences between the groups in Et,
Et deceleration time, and At (P40.05 for all). But
the difference in Et/At reached significance
(P ¼ 0.026).From tissue Doppler systolic time intervals, both
ICTr and ETr were impaired in the patients
compared with controls (P ¼ 0.043 and 0.012,
respectively). Also, IRTr was longer in the patient
group (P ¼ 0.001). As a result of these differences,
RVMPI was significantly higher in the patients
(0.6670.19 and 0.4470.06, Po0.001). Compari-
sons of RVMPI, IRTr, ICTr, and ETr between the
groups are shown in Fig. 2.
LV function
Left atrial dimension, LV dimensions, systolic
function (represented by fractional shortening and
ejection fraction), and wall thickness in patients
with bronchiectasis were similar to that of controls
(Table 3). LV diastolic function, represented by Em,
Am, Em/Am ratio, and deceleration time of Em
were all impaired in the patients group (Po0:05
for all).
Tissue Doppler-derived ICT and IRT were longer,
and ET was shorter in those with bronchiectasis
(P ¼ 0.001, Po0.001, and P ¼ 0.019, respectively).
LVMPI was higher in the patients than in controls
ARTICLE IN PRESS
Table 3 Left heart echocardiographic findings.
Patients with bronchiectasis
(n ¼ 25)
Controls (n ¼ 22) P-value
Left atrium (mm) 3274 3372 0.296
LVEDD (mm) 4575 4974 0.009
LVESD (mm) 3076 3173 0.685
IVSd (mm) 9.671.5 10.371.0 0.088
PWd (mm) 9.2771.1 9.971.1 0.057
LVFS (%) 3575 3774 0.210
LVEF (%) 6577 6775 0.356
Em (cm/s) 62712 70712 0.037
Am (cm/s) 55712 4479 0.002
Em/Am 1.270.3 1.770.5 o0.001
Deceleration time of Em (ms) 259751 208724 o0.001
IRT (ms) 101720 74711 o0.001
ICT (ms) 77725 53714 0.001
ET (ms) 290730 311723 0.019
LVMPI 0.6370.17 0.4170.07 o0.001
Am, late diastolic mitral in-flow velocity; Em, early diastolic mitral in-flow velocity; ET, tissue Doppler-derived heart-rate-
corrected left ventricular ejection time; ICT, tissue Doppler-derived heart-rate-corrected left ventricular isovolumic
contraction time; IRT, tissue Doppler-derived heart-rate-corrected left ventricular isovolumic relaxation time; IVSd,
interventricular septum diastolic thickness; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection
fraction; LVESD, left ventricular end-systolic diameter; LVFS, left ventricular fractional shortening; LVMPI, tissue Doppler-
derived left ventricular myocardial performance index; PWd, left ventricular posterior wall diastolic thickness.
Figure 3 Comparison of the tissue Doppler-derived LVMPI, IRT, ICT, and ET between the patients with bronchiectasis
and controls. [IRT, tissue Doppler-derived heart-rate-corrected left ventricular isovolumic relaxation time; ICT, tissue
Doppler-derived heart-rate-corrected left ventricular isovolumic contraction time; ET, tissue Doppler-derived heart-
rate-corrected left ventricular ejection time; LVMPI, tissue Doppler-derived left ventricular myocardial performance
index.]
M. Gencer et al.1938
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Bronchiectasis, ventricular function 1939(0.6370.17 and 0.4170.07, Po0.001). Compari-
sons of LVMPI, IRT, ICT, and ET between the patients
and controls are illustrated in Fig. 3.Correlations of the RVMPI and LVMPI with
clinical and echocardiographic variables
In the patients with bronchiectasis, RVMPI was
correlated with the number of involved lung lobe,
partial pressure of arterial oxygen, and ET/AT ratio
of pulmonary flow (Po0.05 for all correlation).
LVMPI was not related to these variables. On the
other hand, LVMPI was correlated only with RVMPI
(r ¼ 0.724, Po0.001). Neither LVMPI nor RVMPI was
correlated to age, gender, smoking status, systolic
or diastolic blood pressure, heart rate, PASP, FEV1,
FVC, FEV1/FVC, partial pressure of carbon dioxide,
and bilateral pulmonary involvement (Table 4).Sensitivity and specificity values of RVMPI
and LVMPI for differentiation of
bronchiectatic patients from controls
In the ROC analysis, the area under the curve was
0.929 for the RVMPI and 0.937 for the LVMPI for theTable 4 Correlations of the RVMPI and LVMPI with
clinical and echocardiographic variables.
RVMPI LVMPI
R P R P
Age 0.303 0.181 0.188 0.414
Gender 0.047 0.840 0.128 0.581
Smoking status 0.001 0.998 0.210 0.360
Systolic blood
pressure
0.046 0.842 0.107 0.646
Diastolic blood
pressure
0.134 0.562 0.235 0.305
Heart rate 0.351 0.118 0.351 0.119
PASP 0.75 0.754 0.096 0.686
Pulmonary AT/
ET
0.321 0.033 0.118 0.253
FEV1 0.19 0.934 0.285 0.210
FVC 0.005 0.983 0.149 0.519
FEV1/FVC 0.145 0.531 0.171 0.457
PaCO2 (mmHg) 0.021 0.816 0.112 0.652
PaO2 (mmHg) 0.317 0.041 0.184 0.241
The number of
involved lobe





0.137 0.555 0.130 0.575
LVMPI 0.724 o0.001 — —
Abbreviations as in Tables 1–3.differentiation of the patients with bronchiectasis
from controls.
An RVMPIX0.47 was associated with the most
optimal sensitivity (96%) and specificity (72.7%)
rates for the differentiation of the patients with
bronchiectasis from controls. An RVMPIX0.47 was
found in 30 subjects (63.8%), and the RVMPI was
o0.47 in 17 subjects (36.2%). Of 30 subjects with
RVMPIX0.47, 20 were bronchiectasis patients
(80%), whereas only 1 of 17 subjects with RVMPI
o0.47 were bronchiectasis patients (5.9%,
Po0.001).
An RVMPIp0.45 was associated with a 100%
sensitivity rate, and an RVMPIX0.55 was associated
with a 100% specificity rate for the differentiation
of the patients with bronchiectasis from controls.
Subjects with an RVMPIX0.55 (11 subjects) were all
bronchiectasis patients, and none of those with an
RVMPIp0.45 (12 subjects).
An LVMPIX0.49 was associated with the most
optimal sensitivity (84.0%) and specificity (86.4%)
rates for the differentiation of the patients with
bronchiectasis from controls. An LVMPIX0.49 was
found in 24 subjects (51.1%), and it waso0.49 in 23
subjects (48.9%). Of 24 subjects with LVMPIX0.49,
21 were bronchiectasis patients (87.5%) and only 4
of 23 subjects with LVMPIo0.49 were bronchiecta-
sis patients (17.4%, Po0.001).
An LVMPIp0.37 was associated with 100% sensi-
tivity rate, and an LVMPIX0.52 was associated with
a 100% specificity rate for the differentiation of the
patients with bronchiectasis from controls. Sub-
jects with an LVMPIX0.52 (16 subjects) were all
bronchiectasis patients, and none of those with an
LVMPIp0.37 (6 subjects).Figure 4 RVMPI and LVMPI values of individuals for the
patient and control groups. [LVMPI, tissue Doppler-
derived left ventricular myocardial performance index;
RVMPI, tissue Doppler-derived right ventricular myocar-
dial performance index.]
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M. Gencer et al.1940Figure 4 shows RVMPI and LVMPI values of the
individuals for the patient and control groups.Discussion
This study firstly showed that adult patients with
bronchiectasis demonstrate impairment of right
and left cardiac function when compared to normal
control subjects. We also observed that the
abnormal RV function in patients with bronchiec-
tasis was related to arterial oxygen tension, the
number of involved lung lobe and AT/ET ratio of
pulmonary flow. LV dysfunction in patients with
bronchiectasis was independent of arterial oxygen
tension, respiratory function test parameters, the
parameters that reflect pulmonary arterial pres-
sure, presence of bilateral bronchiectasis, or the
number of involved lobe. RV and LV dysfunctions are
related to each other. Generally, the disturbances
in overall lung function are more dependent on the
extent of involvement than on the anatomic type of
bronchiectasis. With progressive or extensive
bronchiectasis, arterial hypoxemia may develop
secondary to abnormalities in gas exchange in
adjacent areas.9
A number of possible mechanisms might be
considered to explain these findings. The obstruc-
tive defect of airways is present in bronchiecta-
sis.28 Airflow obstruction results from obliterative
bronchiolitis, with or without associated airway
hyper-responsiveness.29 Our findings demonstrated
impaired pulmonary functions in keeping with this
knowledge. Chronic airway obstruction may lead to
hypoxemia and increase in pulmonary vascular
resistance.
Hypoxemia is an important factor that is known
to affect RV and LV functions.7,8,30 Although the
role of hypoxemia and hypercapnia in the develop-
ment of RV dysfunction has been well-documented
in patients with CF,7,8 this issue has not been
evaluated in bronchiectatic patients so far. Both
intermittent and sustained hypoxemias have been
implicated in the pathogenesis of pulmonary
hypertension in animal models, and in humans with
COPD.31,32 Hypoxic pulmonary vasoconstriction
would be expected to induce major RV function
changes in response to increased afterload.32
Chronic hypoxia in patients with bronchiectasis
eventually may lead to increase in pulmonary
vascular resistance, thereby a condition of exces-
sive RV work. Our study showed that the levels of
partial pressure of arterial oxygen were correlated
with RV functions. Hypoxia should exert predomi-
nant effects on the RV because of increased loadingdue to hypoxia-induced pulmonary vasoconstric-
tion.33 On the other hand, negative inotropic effects
of hypoxia may lead to decrease of both LV and RV
systolic performances.34 But arterial oxygen pres-
sure was not related to LVMPI in our study.
In addition, pulmonary hypertension has a major
effect on RV function in patients with various
pulmonary diseases such as CF,8 and COPD.3–5
Researchers suggested the possibility of hemody-
namic alterations in the lungs of patients with
bronchiectasis.35 It is known that destruction of the
structural components of the bronchial wall occurs
in bronchiectasis. Diffuse systemic-pulmonary ana-
stomoses occur in granulomatous tissue within
bronchiectatic segments. When such anastomoses
are enlarged to a certain degree, oxygenated blood
would shunt from high-pressure systemic bronchial
and intercostal arteries to the low-pressure pul-
monary circulation. Chronic shunt flow may lead to
increase in pulmonary arterial pressure, and there-
by in RV work. The association of RVMPI with
involved lobe number may be due to the amount of
the shunt flow. However, we were not able to assess
the presence of systemic-pulmonary anastomoses.
Separately, we were able to document the pre-
sence of pulmonary hypertension (PASP430mmHg)
in only one of the 25 patients studied by assessing
tricuspid regurgitation. There was an insignificant
difference in PASP between the patients and
controls. Furthermore, PASP was not correlated
with RVMPI or LVMPI.
The Doppler echocardiographic evaluation of
pulmonary hypertension usually relies on the
measurement of the maximal velocity of tricuspid
valve regurgitant jet and the calculation of a
systolic trans-tricuspid pressure gradient based on
the simplified form of the Bernouilli equation.23
The resulting systolic pulmonary artery pressure
estimate is generally correlated to invasively
measured pressure. Mean pulmonary artery pres-
sure can also be estimated from the morphology of
pulmonary artery blood flow, with a decreased AT/
ET in proportion to increased mean pulmonary
artery pressure.24 These measurements may be
more sensitive to pulmonary-vasoconstriction-re-
lated increase in RV afterload.24 In the current
study, it is shown that there was a decreased
pulmonary flow AT/ET ratio in patients with
bronchiectasis, indicating pulmonary vasoconstric-
tion and increased pulmonary vascular resistance.
In addition, in contrast to PASP obtained by
tricuspid regurgitation, decreased ET/AT levels
were associated with RVMPI. Why PASP did not
correlate to RVMPI while AT/ET did in the present
study is unclear. It may be that PASP remains less
sensitive than AT/ET to increase in RV afterload.
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Bronchiectasis, ventricular function 1941LV dysfunctions in COPD or CF have been shown
and related to pulmonary arterial pressure3–5 and
septal leftward shift.4 In a new study, we have
demonstrated that LV myocardial performance is
also related to RV performance.5 As seen in that
study, LVMPI was related to RVMPI in the current
study. The heart is composed of two muscular
pumps that are connected in series to one another
by the pulmonary and systemic circulations. The
functional integration of these pumps is not only
through their series of arrangements but also
through their anatomic features and the presence
of the pericardium.36 Furthermore, RV and LV share
the interventricular septum. Thus, alterations in RV
size and function will influence LV performance.
The etiology of the observed RV and LV dysfunc-
tions in patients with bronchiectasis is potentially
multifold. Potential mechanisms should be assessed
in the large future studies.
Although patients with bronchiectasis had normal
LV and RV conventional systolic function para-
meters, the RVMPI and LVMPI were significantly
different from control subjects’ levels. The MPI has
been shown to be better than conventional RV and
LV systolic function parameters in predicting the
prognosis and survival.15–17 Therefore, the in-
creased RVMPI and LVMPI, even when RV and LV
conventional systolic function parameters are
normal, in patients with bronchiectasis strongly
suggest the presence of RV and LV dysfunctions. The
elevations of the RVMPI and LVMPI in the patients
were caused not only by prolongation of diastolic
time intervals (IRTr and IRT) but also by differences
of systolic time intervals (ICTr, ETr, ICT and
ET). Therefore, it can be suggested that both
systolic and diastolic dysfunctions are present in
bronchiectasis.
According to ROC analysis results, RVMPI and
LVMPI can reliably separate the patients with
bronchiectasis from controls. There was insignif-
icant overlapping between the groups in both
parameters. Therefore, these variables can be
reliably used in the management of bronchiectatic
patients.
Conventional pulsed wave Doppler-derived MPI is
proposed as a potentially useful predictor of
systolic and diastolic cardiac functions.15–17 How-
ever, there is an important limitation in that the
interval between the end and the onset of mitral
inflow, and ejection time is measured sequentially
and not on the same cardiac cycle in this method.
Because of this, results are probably less reliable in
the presence of heart rate fluctuation even if
normal in sinus rhythm is present. Pulsed wave
Doppler tissue, as used in this study, can simulta-
neously record systolic and diastolic mitral annularvelocities. Determination of MPI derived by pulsed
wave Doppler tissue requires measurement of only
two simple intervals on the same cardiac cycle. It is
shown that MPI derived from the mitral annulus by
pulsed wave Doppler tissue correlates well with MPI
derived by conventional pulsed wave Doppler and
can be used as a simple and reliable method for
assessing LV myocardial performance even in the
presence of heart rate fluctuation in patients with
in sinus rhythm.37 Therefore, we used pulsed wave
Doppler tissue in obtaining the MPI.
Cardiac function has been assessed in only two
previous studies in patients with bronchiectasis. In
one of these, cardiac functions were assessed
primarily in CF, and only 9 patients with bronch-
iectasis enrolled.38 RV systolic function was found
to be impaired compared to controls by radio-
nuclide ventriculography. RV diastolic function was
not assessed in that study. LV ejection fraction was
similar to the controls’ levels in the patients with
bronchiectasis. The assessment of LV diastolic
function by radionuclide ventriculography showed
no difference than controls. Due to the too low
patients’ number, the results of this study may be
less reliable. Another study that assessed ventri-
cular function in bronchiectasis was performed in a
group of children patients.39 In that study, there
was not a control group, and only LV systolic and
diastolic functions were assessed by conventional
methods. LV systolic function was found to be
normal and diastolic function to be impaired.
Interestingly, there was an inverse relation be-
tween isovolumic relaxation time and clinical score
of bronchiectasis, indicating that more advanced
disease is related to less impairment of LV diastolic
function. It is very important to consider that, in
our study, enough number of patients were enrolled
to the study, they were compared with controls,
and both RV and LV systolic and diastolic functions
were assessed both by conventional methods and
by a novel and more sensitive method.
This study demonstrated RV and LV dysfunctions
in patients with bronchiectasis. However, the
clinical significance of these results is not clear.
Further research is needed to investigate the
prognostic significance of RV and LV dysfunctions
because of bronchiectasis. In this study, heart rate
was different among the groups. Doppler-derived
isovolumic relaxation and contraction times, and
ejection time have been shown to be dependent on
heart rate.15,36 Because of this, these intervals
were adjusted for heart rate in our study. On the
other hand, the MPI is not greatly influenced by
changes in heart rate.40 Also, systolic blood
pressure was different between the groups. How-
ever, data regarding the impact of blood pressure
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demonstrated that the MPI is not greatly influenced
by changes in blood pressure,41 another one
demonstrated that it is influenced by increasing
blood pressure.42 In our study, however, there was
no association between systolic blood pressure and
the MPI according to correlation test results.
Therefore, it can be suggested that higher systolic
blood pressure does not play a role in the
difference of MPI between the groups.
In conclusion, by using pulsed wave tissue
Doppler echocardiographic technique, we have
demonstrated a marked LV and RV dysfunctions in
patients with bronchiectasis. RV function in these
patients is related to arterial oxygen tension, the
number of involved lung lobe and AT/ET ratio of
pulmonary flow. LV dysfunction level is associated
only with RV functions.References
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